Direct Gene Editing Inside the Body Nears First US Health Approval

Washington, Sunday, 15 November 2026.
The FDA’s pending decision on Intellia’s liver-targeted therapy could mark the first medicine to edit genes directly inside patients, bypassing costly laboratory cell modification to expand patient reach.